Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309523 | 0.87 | MEN1 (0.43) | NPC1RAB9APOLBTDP1L3MBTL1 | |
| SCHEMBL6305551 | 0.86 | CFTR (0.39) | ALDH1A1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6305575 | 0.84 | TYK2 (0.40) | ROCK2ROCK1POLBL3MBTL1 | |
| SCHEMBL6304501 | 0.84 | MAPT (0.42) | ALDH1A1NPC1RAB9APOLBL3MBTL1 | |
| SCHEMBL6308800 | 0.83 | KDM4E (0.42) | ALDH1A1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6304649 | 0.83 | HTT (0.47) | ALDH1A1POLBRECQLTDP1 | |
| SCHEMBL6310478 | 0.82 | KMT2A (0.38) | ALDH1A1NPC1RAB9A | |
| SCHEMBL6310006 | 0.82 | RAB9A (0.43) | ALDH1A1NPC1RAB9ACYP2D6POLB | |
| SCHEMBL6309111 | 0.82 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9ACYP2D6POLB | |
| SCHEMBL6302891 | 0.81 | HRH1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | ALDH1A1 1197/4885ROCK2 3933/4885ROCK1 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.